Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)
/PRNewswire/ -- Eluminex Biosciences today announced the completion of clinical enrollment in Part A (N=5) of a two-part pivotal study (CLARITY) evaluating a...
Source: prnewswire.com